Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which works better: one antibiotic or two for this superbug?

NCT ID NCT07593547

Knowledge-focused Sponsor: Instituto de Investigación Sanitaria Gregorio Marañón Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 790 adults with S. maltophilia infections, a hard-to-treat bacteria. Researchers will compare patients who got one antibiotic versus those who got a combination, to see which group has fewer deaths within 30 days. The goal is to find the best treatment approach using real-world data.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors choose the best treatment strategy for S. maltophilia infections, potentially reducing deaths.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test a new drug, only compares existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 790 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The selection criterion was the isolation of S. maltophilia in consecutive clinical samples from hospitalised adult patients, identified in microbiology laboratories between 2024 and 2025. The investigators first estimated the incidence of the S. maltophilia isolations per 1,000 admissions. Then, differenced episodes of infection defined if the treating physician considered of clinical significance the S. maltophilia isolation. Different infection episodes were considered from 30 days after the index episode.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients * S. maltophilia infections * Different episodes if a new infection ocurred \> 30 days since the index episode Exclusion Criteria: * isolates obtained from patients outside of hospital admission * microbiological or clinical colonization * hospitalizations shorter than 72 hours since the time zero * patients who died in the first 72 hours since the time zero or who were in imminent risk of death * polymicrobial infections * receipt of inappropriate therapy after the time of the emulated randomization, defined as the absence of in vitro active antimicrobials or the administration of active antimicrobials for less than 48 hours * absence of data outcomes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bloodstream infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis bacterial pneumonia Infections Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bloodstream infection Pneumonia - bacterial S maltophilia infections S. maltophilia infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Microbiology and Infectious Disease Department, Hospital General Universitario Gregorio Marañón

    RECRUITING

    Madrid, Madrid, 28007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.